Search results
Continuing Forward: Senate Leaders Release an AI Policy Roadmap
The National Law Review· 5 hours agoFrom intellectual property reforms and substantial funding for AI research to sector-specific rules...
Kansas bills that sought protection from Chinese espionage and market manipulation fizzle
The Topeka Capital-Journal via Yahoo News· 10 hours agoSystem from countries of concern was bundled into a larger bill that also reforms KPERS increases...
AI Watch: Global regulatory tracker - France | JD Supra
JD Supra· 1 hour agoFrance actively participates in international efforts and the EU AI Act negotiations, and proposes sector-specific laws. Currently, there are no specific laws, statutory rules, or regulations ...
How to reduce Scope 3 emissions?
Fast Company Magazine· 1 day agoIn talking with supply chain leaders around the world, I often hear that reducing Scope 3 greenhouse gas emissions (GHGs) is either too confounding or...
Council Post: Understanding The Legal And Regulatory Landscape Of Generative AI
Forbes· 4 days agoGenerative AI is revolutionizing content creation but also brings privacy and legal issues.
Data Privacy Guide - Spain | JD Supra
JD Supra· 3 days agoIntroduction - We have compiled the main differences between the REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL...
The Debate on Data Scraping Was Almost Over—Until Generative AI Rekindled It | Legaltech News
Law.com· 1 day agoData scraping isn’t new—in fact, some suggest the practice may be almost as old as the World Wide...
Thoughts on RDRS for Brand Owners
CircleID· 4 days agoBut first up, what is RDRS?
CFTC Sharpens Focus on Artificial Intelligence with Appointment of Chief Artificial Intelligence...
JD Supra· 1 day agoOn May 1, 2024, the U.S. Commodity Futures Trading Commission (“CFTC” or the “Commission”) announced Dr. Ted Kaouk as the Commission’s first Chief Artificial Intelligence (“AI”) Officer. As ...
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Digital Journal· 4 days agoPF614's Phase 3 Clinical Plans Affirm the Path to Regulatory ApprovalFDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / ...
